Giancarlo Marra1, Guillaume Ploussard2, Piet Ost3, Pieter J L De Visschere3, Alberto Briganti4, Giorgio Gandaglia4, Derya Tilki5, Christian I Surcel6, Igor Tsaur7, Roderick C N Van Den Bergh8, Alexander Kretschmer9, Hendrik Borgmann10, Paolo Gontero11, Hashim U Ahmed12, Massimo Valerio13. 1. Department of Urology, San Giovanni Battista Hospital, Città della Salute e della Scienza and University of Turin, Turin, Italy. Electronic address: drgiancarlomarra@gmail.com. 2. Department of Urology, Saint Jean Languedoc Hospital and Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France. 3. Department of Urology and Radiology, Ghent University, Ghent, Belgium. 4. Department of Urology, Vita e Salute University and San Raffaele Hospital, Milan, Italy. 5. Martini-Klinik Prostate Cancer Center, University Hospital Hamburg- Eppendorf, Hamburg, Germany; Department of Urology, University Hospital Hamburg- Eppendorf, Hamburg, Germany. 6. Department of Urology, Fundeni Clinical Institute, Bucharest, Romania. 7. Department of Urology, University of Mainz, Mainz, Germany. 8. Department of Urology, Antonius Hospital, Utrecht, The Netherlands. 9. Department of Urology, Ludwig-Maximilians-University of Munich, Munich, Germany. 10. Department of Urology, University Hospital of Mainz, Mainz, Germany. 11. Department of Urology, San Giovanni Battista Hospital, Città della Salute e della Scienza and University of Turin, Turin, Italy. 12. Division of Surgery, Department of Surgery and Cancer, Imperial College London, London, UK; Department of Urology, Imperial College Healthcare NHS Trust, London, UK. 13. Department of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Abstract
INTRODUCTION: The urological community's opinion over focal therapy (FT) for prostate cancer (PCa) has never been assessed. Our aim was to investigate the current opinion on FT in the European urological community. METHODS: A 25-item questionnaire was devised according to the Cherries checklist and distributed through SurveyMonkey using a web link from November 2016 to October 2017. After a pilot validation (n = 40 urologists), the survey was sent through EAU and 9 other national European urological societies mailing list. Twitter was also used. RESULTS: We received 484 replies from 51 countries. Almost half (44.8%, n = 217) stated FT would represent a step forward, and 52.0% (n = 252) would suggest FT to a patient. Almost three-quarters (70.8%, n = 343) agreed FT will become a standard option after improvements in patient selection (n = 66) or when its effectiveness will be proven (n = 78), or both (n = 199). Most frequently used definition of FT was treatment of all significant (life-threatening) cancer foci whilst leaving untreated the rest of the gland (39.3%, n = 190). FT use was considered as an alternative to whole-gland treatments by 29.7% (n = 144), and to AS by 25.0% (n = 121). On multivariate analysis, FT availability and publications were associated with a positive opinion on FT. Conversely, attending International congresses, treating high PCa volumes and high percentages of high-risk PCa was associated with a negative opinion. CONCLUSIONS: FT is considered as an attractive option for PCa treatment by the European urological community sampled by our survey. FT availability positively influences these thoughts. The present survey suggests whilst some early adopters already embraced FT, the relative majority of the urological community is prone to embrace FT in the near future, once current areas of debate are solved.
INTRODUCTION: The urological community's opinion over focal therapy (FT) for prostate cancer (PCa) has never been assessed. Our aim was to investigate the current opinion on FT in the European urological community. METHODS: A 25-item questionnaire was devised according to the Cherries checklist and distributed through SurveyMonkey using a web link from November 2016 to October 2017. After a pilot validation (n = 40 urologists), the survey was sent through EAU and 9 other national European urological societies mailing list. Twitter was also used. RESULTS: We received 484 replies from 51 countries. Almost half (44.8%, n = 217) stated FT would represent a step forward, and 52.0% (n = 252) would suggest FT to a patient. Almost three-quarters (70.8%, n = 343) agreed FT will become a standard option after improvements in patient selection (n = 66) or when its effectiveness will be proven (n = 78), or both (n = 199). Most frequently used definition of FT was treatment of all significant (life-threatening) cancer foci whilst leaving untreated the rest of the gland (39.3%, n = 190). FT use was considered as an alternative to whole-gland treatments by 29.7% (n = 144), and to AS by 25.0% (n = 121). On multivariate analysis, FT availability and publications were associated with a positive opinion on FT. Conversely, attending International congresses, treating high PCa volumes and high percentages of high-risk PCa was associated with a negative opinion. CONCLUSIONS: FT is considered as an attractive option for PCa treatment by the European urological community sampled by our survey. FT availability positively influences these thoughts. The present survey suggests whilst some early adopters already embraced FT, the relative majority of the urological community is prone to embrace FT in the near future, once current areas of debate are solved.
Authors: R Bischoff; M Chaloupka; T Westhofen; T Grimm; B Schlenker; P Weinhold; D Tilki; C G Stief; A Kretschmer Journal: Urologe A Date: 2019-05 Impact factor: 0.639
Authors: Giancarlo Marra; Taimur T Shah; Daniele D'Agate; Alessandro Marquis; Giorgio Calleris; Luca Lunelli; Claudia Filippini; Marco Oderda; Marco Gatti; Massimo Valerio; Rafael Sanchez-Salas; Alberto Bossi; Juan Gomez-Rivas; Francesca Conte; Desiree Deandreis; Olivier Cussenot; Umberto Ricardi; Paolo Gontero Journal: Front Surg Date: 2022-06-07
Authors: Sonia S Hur; Michael Tzeng; Eliza Cricco-Lizza; Spyridon P Basourakos; Miko Yu; Jessica Ancker; Erika Abramson; Christopher Saigal; Ashley Ross; Jim Hu Journal: BMJ Surg Interv Health Technol Date: 2021-06
Authors: Antony Pellegrino; Giuseppe O Cirulli; Elio Mazzone; Francesco Barletta; Simone Scuderi; Mario de Angelis; Giuseppe Rosiello; Giorgio Gandaglia; Francesco Montorsi; Alberto Briganti; Armando Stabile Journal: Ann Transl Med Date: 2022-07